Cordlife Group Limited
Annual Report 2016
37
Corporate
Governance Report
Principle 9: Disclosure on Remuneration
A breakdown showing the level and mix of each individual Director’s remuneration for FY2016 is disclosed in the table
below:
Other
short-term
Directors
Salary
Bonus
benefits Allowances Fees
Total
(%)
(%)
(%)
(%)
(%)
(%)
Above $1,500,000 to $2,000,000
Yee Pinh Jeremy
(1)
Executive Director and CEO
36
62
–
2
–
100
$250,000 and below
Dr Wong Chiang Yin
(2)
Executive Director and Group CEO
–
–
–
–
–
–
Tan Poh Lan
Executive Director and Group COO
95
–
–
5
–
100
Other
short–term
Directors
Salary
Bonus
benefits Allowances Fees
Total
(S$)
(S$)
(S$)
(S$)
(S$)
(S$)
Dr Ho Choon Hou
(6)
Chairman, Non-Executive Non-
–
–
–
–
238,000 238,000
Independent Director
Ho Sheng
(6)
Independent Director
–
–
–
–
83,000
83,000
Dr Goh Jin Hian
Independent Director
–
–
–
–
83,000
83,000
Eileen Tay-Tan Bee Kiew Independent Director
–
–
–
–
83,000
83,000
Joseph Wong Wai Leung Independent Director
–
–
–
–
83,000
83,000
Chen Bing Chuen
Non-Independent Non-Executive
–
–
–
–
–
–
Albert
(3)
Director
Wang Taiyang
(3)
Non-Independent Non-Executive
–
–
–
–
–
–
Director
Hu Minglie
(3)
Non-Independent Non-Executive
–
–
–
–
–
–
Director
Ho Han Siong
Non-Independent Non-Executive
–
–
–
–
–
–
Christopher
(4)
Director
Gary Xie Guojun
(5)
Non-Independent Non-Executive
–
–
–
–
–
–
Director
(1) Mr Yee Pinh Jeremy resigned as the Executive Director and Chief Executive Officer of the Company with effect from 21 March
2016.
(2) Dr Wong Chiang Yin was appointed as a Director and Group Chief Executive Officer of the Company with effect from 1 July
2016, therefore no remuneration was paid to him during FY2016.
(3) Mr Chen Bing Chuen Albert, Ms Wang Taiyang and Mr Hu Minglie were appointed as NINEDs of the Company with effect from
29 April 2016. They have agreed to waive their directors’ fees for FY2016 and FY2017.
(4) Mr Ho Han Siong Christopher was appointed as a NINED of the Company with effect from 29 April 2016 and resigned on 4
October 2016. He has agreed to waive his director’s fee for FY2016 and FY2017.
(5) Mr Gary Xie Guojun was appointed as a NINED of the Company with effect from 29 April 2016 and resigned on 30 September
2016. He has agreed to waive his director’s fee for FY2016 and FY2017.
(6) For FY2016, extraordinary Directors’ fees of
was proposed for Dr Ho Choon Hou and Mr Ho Sheng to recognise
the extra work put in and accumulation of time spent by the Board Chairman and the Lead Independent Director for the
transactions with China Cord Blood Corporation (“CCBC”) and management of the Board and the Company in times of Board
and Management changes during the year.
